Antibodies
LY2090314
- 貨號 Cat. No.
- S7063
- 規格 Size
- 5~200mg
- 品牌 Brand
- Selleckchem
Description
LY2090314
Catalog No.S7063
LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 1/2.
| Availability |
|---|
The item is temporarily out of stock. Please leave your email address and we will inform you when we have it in stock. Just click the Arrival Notice and leave your email address to get 10% off. Arrival Notice |
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
| Description | LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 1/2. | |||||
|---|---|---|---|---|---|---|
| Targets | GSK-3α | GSK-3β | ||||
| IC50 | 1.5 nM | 0.9 nM [1] | ||||
| In vitro | LY2090314 selectively inhibits the activity of GSK-3 by interrupting ATP binding. LY2090314 is able to stabilize β-catenin. LY2090314 shows limited efficacy as monotherapy. LY3090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer cell lines in vitro. [1] | |||||
| In vivo | LY3090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer xenografts. [1] | |||||
| Features | ||||||
Protocol(Only for Reference)
References
Clinical Trial Information( data from http://clinicaltrials.gov)
| NCT Number | Recruitment | Conditions | Sponsor /Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01287520 | Completed | Advanced Cancer | Eli Lilly and Company | 2007-11 | Phase 1 |
| NCT01214603 | Completed | Leukemia | Eli Lilly and Company | 2010-11 | Phase 2 |
| NCT01632306 | Recruiting | Pancreatic Cancer | Eli Lilly and Company|Mayo Clinic | 2013-03 | Phase 1|Phase 2 |
Chemical Information
| Molecular Weight (MW) | 512.53 |
|---|---|
| Formula | C28H25FN6O3 |
| CAS No. | 603288-22-8 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | N/A |
| Solubility (25°C) * | In vitro | DMSO | mg/mL (<1 mM) |
|---|---|---|---|
| Water | mg/mL (<1 mM) | ||
| Ethanol | mg/mL (<1 mM) | ||
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name | 3-(9-fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione |
|---|
